Author

D. Wald

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1

Frequent Co-Authors

A. Bruscaggin· 1 shared A. J. Arribas· 1 shared A. Marins dos Santos· 1 shared A. Stathis· 1 shared C. Ishihama Suzuki· 1 shared C. M. Watanabe· 1 shared C. Tarantelli· 1 shared D. Rossi· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Bruscaggin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Induction of expansion of ex vivo NK cells using a new feeder cell built in Brazil. An extended flow cytometry evaluation of K562.mbIL21.4BBL

C. M. Watanabe, C. Ishihama Suzuki, A. Marins dos Santos, T. P. A. Aloia, G. Lee, D. Wald, O. K. Okamoto, J. T. C. d. Azevedo, J. A. P. d. Godoy, F. P. S. Santos, R. Weinlich, L. N. Kerbauy, J. M. Kutner, R. d. M. A. Paiva, N. Hamerschlak

This paper develops a Brazilian feeder cell, K562.Clone1, which expands NK cells ex vivo more than 100-fold while preserving their antitumor activity.

bioRxiv · Feb 23, 2024 · PreprintCancer Biology

Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

C. Tarantelli, D. Wald, N. Munz, F. Spriano, A. Bruscaggin, E. Cannas, L. Cascione, E. Gaudio, A. J. Arribas, S. Manjappa, G. Golino, L. Scalise, E. Zucca, A. Stathis, P. H. Van Berkel, , F. Bertoni

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

bioRxiv · Aug 17, 2023 · PreprintCancer Biology